Literature DB >> 22008062

Association between BclI polymorphism in the NR3C1 gene and in vitro individual variations in lymphocyte responses to methylprednisolone.

Eva Cuzzoni1, Sara De Iudicibus, Fiora Bartoli, Alessandro Ventura, Giuliana Decorti.   

Abstract

WHAT IS ALREADY KNOWN ABOUT THIS SUBJECT: In vitro lymphocyte steroid sensitivity has been suggested as a useful tool to predict in vivo response to glucocorticoid treatment in different inflammatory chronic diseases. A correlation between genetic polymorphisms and clinical response to glucocorticoids has been demonstrated in these patients. WHAT THIS STUDY ADDS: The BclI polymorphism in the glucocorticoid receptor (NR3C1) gene is associated with higher methylprednisolone potency in vitro. The combined evaluation of the in vitro sensitivity to methylprednisolone and BclI polymorphism could represent an aid for physicians to adjust therapy a priori. AIM To evaluate the association between the in vitro sensitivity of peripheral blood mononuclear cells (PBMCs) to methylprednisolone (MP) and the presence of genetic polymorphisms involved in glucocorticoid (GC) response.
METHODS: In vitro MP inhibition of the proliferation of lymphocytes stimulated with concanavalin A was determined. Non linear regression of dose-response data was performed computing the MP concentration required to reduce proliferation to 50% (IC(50) ). The maximum inhibition achievable at the highest MP concentration (I(max) ) was also calculated. Moreover, the Taqman technique was used to analyze the BclI polymorphism in the NR3C1 gene and the Leu155His polymorphism in the NALP1 gene.
RESULTS: A significant association between the BclI mutated genotype and an increased in vitro sensitivity to GCs was observed.
CONCLUSIONS: The a priori evaluation of the BclI polymorphism, associated with a lymphocyte proliferation assay, could represent a useful diagnostic tool for the optimization of steroid treatment.
© 2011 The Authors. British Journal of Clinical Pharmacology © 2011 The British Pharmacological Society.

Entities:  

Mesh:

Substances:

Year:  2012        PMID: 22008062      PMCID: PMC3376441          DOI: 10.1111/j.1365-2125.2011.04130.x

Source DB:  PubMed          Journal:  Br J Clin Pharmacol        ISSN: 0306-5251            Impact factor:   4.335


  15 in total

Review 1.  Molecular mechanisms of immunomodulatory activity of glucocorticoids.

Authors:  Carlo Riccardi; Stefano Bruscoli; Graziella Migliorati
Journal:  Pharmacol Res       Date:  2002-05       Impact factor: 7.658

2.  Association of BclI polymorphism of the glucocorticoid receptor gene locus with response to glucocorticoids in inflammatory bowel disease.

Authors:  Sara De Iudicibus; Gabriele Stocco; Stefano Martelossi; Ilenia Drigo; Stefania Norbedo; Paolo Lionetti; Elena Pozzi; Arrigo Barabino; Giuliana Decorti; Fiora Bartoli; Alessandro Ventura
Journal:  Gut       Date:  2007-09       Impact factor: 23.059

3.  Guide to Receptors and Channels (GRAC), 4th Edition.

Authors: 
Journal:  Br J Pharmacol       Date:  2009-11       Impact factor: 8.739

4.  NALP1 in vitiligo-associated multiple autoimmune disease.

Authors:  Ying Jin; Christina M Mailloux; Katherine Gowan; Sheri L Riccardi; Greggory LaBerge; Dorothy C Bennett; Pamela R Fain; Richard A Spritz
Journal:  N Engl J Med       Date:  2007-03-22       Impact factor: 91.245

5.  Predicting therapeutic outcome in severe ulcerative colitis by measuring in vitro steroid sensitivity of proliferating peripheral blood lymphocytes.

Authors:  S D Hearing; M Norman; C S Probert; N Haslam; C M Dayan
Journal:  Gut       Date:  1999-09       Impact factor: 23.059

6.  Differential glucocorticoid responsiveness of dialysis patients' lymphocytes.

Authors:  W A Briggs; Z H Gao; P J Scheel; J F Burdick; L F Gimenez; M J Choi
Journal:  Perit Dial Int       Date:  1996 Jul-Aug       Impact factor: 1.756

7.  Genetic predictors of glucocorticoid response in pediatric patients with inflammatory bowel diseases.

Authors:  Sara De Iudicibus; Gabriele Stocco; Stefano Martelossi; Margherita Londero; Egle Ebner; Alessandra Pontillo; Paolo Lionetti; Arrigo Barabino; Fiora Bartoli; Alessandro Ventura; Giuliana Decorti
Journal:  J Clin Gastroenterol       Date:  2011-01       Impact factor: 3.062

8.  Glucocorticoid receptor polymorphism, skin vasoconstriction, and other metabolic intermediate phenotypes in normal human subjects.

Authors:  M Panarelli; C D Holloway; R Fraser; J M Connell; M C Ingram; N H Anderson; C J Kenyon
Journal:  J Clin Endocrinol Metab       Date:  1998-06       Impact factor: 5.958

9.  Response to glucocorticoid treatment in rheumatoid arthritis: in vitro cell mediated immune assay predicts in vivo responses.

Authors:  B W Kirkham; M M Corkill; S C Davison; G S Panayi
Journal:  J Rheumatol       Date:  1991-06       Impact factor: 4.666

10.  Individual variations in lymphocyte-responses to glucocorticoids in patients with bronchial asthma: comparison of potencies for five glucocorticoids.

Authors:  T Hirano; M Homma; K Oka; H Tsushima; T Niitsuma; T Hayashi
Journal:  Immunopharmacology       Date:  1998-07
View more
  11 in total

1.  MicroRNAs and Glucocorticoid-Induced Apoptosis in Lymphoid Malignancies.

Authors:  Ronit Vogt Sionov
Journal:  ISRN Hematol       Date:  2013-01-29

2.  MIF plasma level as a possible tool to predict steroid responsiveness in children with idiopathic nephrotic syndrome.

Authors:  Eva Cuzzoni; Raffaella Franca; Sara De Iudicibus; Annalisa Marcuzzi; Marianna Lucafò; Marco Pelin; Diego Favretto; Elena Monti; William Morello; Luciana Ghio; Claudio La Scola; Francesca Mencarelli; Andrea Pasini; Giovanni Montini; Giuliana Decorti; Gabriele Stocco
Journal:  Eur J Clin Pharmacol       Date:  2019-08-28       Impact factor: 2.953

3.  Failure of interferon-γ pre-treated mesenchymal stem cell treatment in a patient with Crohn's disease.

Authors:  Andrea Taddio; Alberto Tommasini; Erica Valencic; Ettore Biagi; Giuliana Decorti; Sara De Iudicibus; Eva Cuzzoni; Giuseppe Gaipa; Raffaela Badolato; Alberto Prandini; Andrea Biondi; Alessandro Ventura
Journal:  World J Gastroenterol       Date:  2015-04-14       Impact factor: 5.742

4.  Clinical relevance of the glucocorticoid receptor gene polymorphisms in glucocorticoid-induced ocular hypertension and primary open angle glaucoma.

Authors:  Xiu-Qing Wang; Zhao-Xia Duan; Xiang-Ge He; Xi-Yuan Zhou
Journal:  Int J Ophthalmol       Date:  2015-02-18       Impact factor: 1.779

Review 5.  Mechanisms behind context-dependent role of glucocorticoids in breast cancer progression.

Authors:  Henriett Butz; Attila Patócs
Journal:  Cancer Metastasis Rev       Date:  2022-06-27       Impact factor: 9.264

6.  Pharmacogenetics and induction/consolidation therapy toxicities in acute lymphoblastic leukemia patients treated with AIEOP-BFM ALL 2000 protocol.

Authors:  R Franca; P Rebora; N Bertorello; F Fagioli; V Conter; A Biondi; A Colombini; C Micalizzi; M Zecca; R Parasole; F Petruzziello; G Basso; M C Putti; F Locatelli; P d'Adamo; M G Valsecchi; G Decorti; M Rabusin
Journal:  Pharmacogenomics J       Date:  2015-12-08       Impact factor: 3.550

7.  Glucocorticoid receptor BclI polymorphism associates with immunomodulatory response to stress hormone in human peripheral blood mononuclear cells.

Authors:  L Xiang; G D Marshall
Journal:  Int J Immunogenet       Date:  2012-11-23       Impact factor: 1.466

8.  Identification of the Core MicroRNAs and Potential Molecular Mechanismsin Sarcoidosis Using Bioinformatics Analysis.

Authors:  Yuan Cao; Hua Zhang; Lulu Zheng; Qiao Li
Journal:  Front Mol Biosci       Date:  2021-05-13

9.  Association Between N363S and BclI Polymorphisms of the Glucocorticoid Receptor Gene (NR3C1) and Glucocorticoid Side Effects During Childhood Acute Lymphoblastic Leukemia Treatment.

Authors:  Meriç Kaymak Cihan; Halil Gürhan Karabulut; Nüket Yürür Kutlay; Hatice Ilgın Ruhi; Ajlan Tükün; Lale Olcay
Journal:  Turk J Haematol       Date:  2017-02-09       Impact factor: 1.831

10.  Association between NR3C1 rs41423247 polymorphism and depression: A PRISMA-compliant meta-analysis.

Authors:  Qiuju Peng; Huacheng Yan; Yuguan Wen; Chongfa Lai; Lei Shi
Journal:  Medicine (Baltimore)       Date:  2018-09       Impact factor: 1.889

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.